Light chain deposition disease (LCDD) is a rare condition in which abnormal protein fragments, called light chains, build up in organs throughout the body. These light chains are produced by a rogue clone of immune cells and accumulate most often in the kidneys, where they cause progressive damage. The median age at diagnosis is 56 years, and while the disease is serious, median patient survival is around 14 years with treatment.
How Light Chains Damage Organs
Your immune system normally produces antibodies made of two types of protein: heavy chains and light chains. In LCDD, a small group of abnormal B cells (a type of immune cell) overproduces one specific light chain. These excess light chains circulate through the bloodstream and get filtered by the kidneys, where they stick to tissue and form granular deposits that don’t belong there.
The deposits trigger a damaging chain reaction. Inside the kidney’s filtering units (glomeruli), specialized cells respond to the buildup by producing excessive amounts of structural protein, essentially scarring the tissue. Over time, this creates a characteristic pattern called nodular glomerulosclerosis, where the kidney’s tiny filters become clogged with scar-like nodules. The light chains also coat the membranes surrounding kidney tubules, thickening them and further impairing function.
Kappa-type light chains are involved more often than lambda-type. The kappa chains in LCDD have unusual structural features, including water-repelling amino acid substitutions that cause them to clump together spontaneously into small aggregates. These aggregates form the granular deposits that distinguish LCDD from other protein-deposition diseases.
Connection to Blood Cancers
LCDD doesn’t arise on its own. It develops alongside an underlying blood cell disorder that drives the overproduction of light chains. Between 11% and 65% of cases occur in people with multiple myeloma. A larger portion, 32% to 86%, is linked to a precancerous condition called monoclonal gammopathy of undetermined significance (MGUS), where abnormal proteins are present in the blood but haven’t yet caused major organ damage through the blood disorder itself. A small percentage of cases (2% to 3%) are tied to other lymphoproliferative disorders.
Symptoms and How It Shows Up
Because the kidneys bear the brunt of light chain deposits, the most common signs are kidney-related. Protein spilling into the urine (proteinuria) is often one of the earliest detectable abnormalities. As kidney function declines, you may notice swelling in your legs or around your eyes, fatigue, decreased urine output, or unexplained weight gain from fluid retention. Some people have nephrotic-range protein loss (more than 3 grams per day in urine), though the amount varies widely.
Light chains can also deposit in organs beyond the kidneys, including the heart, liver, and nerves, though renal involvement dominates the clinical picture. The kidneys are particularly vulnerable because they naturally filter and process free light chains as part of their everyday function, concentrating these abnormal proteins in exactly the tissues where they do the most harm.
How LCDD Differs From Amyloidosis
LCDD is often confused with AL amyloidosis because both involve light chain deposits in organs. The key difference is in how the proteins arrange themselves. In AL amyloidosis, light chains fold into organized, fibril-like sheets that stain positive with a dye called Congo red and show a characteristic apple-green color under polarized light. In LCDD, the deposits are granular and non-organized. They do not stain with Congo red. This distinction matters because the two diseases behave differently, progress at different rates, and may respond to different treatment intensities.
On a kidney biopsy, LCDD shows a distinctive pattern: linear staining along the basement membranes of both the glomeruli and tubules when tested with antibodies specific to one light chain type. This uniform, ribbon-like pattern, combined with the nodular scarring visible under a standard microscope, is what confirms the diagnosis.
Diagnosis
A kidney biopsy is the definitive diagnostic step. Pathologists examine the tissue using three complementary techniques: standard light microscopy to spot nodular scarring and membrane thickening, immunofluorescence to identify which type of light chain (kappa or lambda) is deposited and confirm it’s restricted to just one type, and electron microscopy to characterize the granular (non-fibrillar) nature of the deposits.
Blood tests also play a role. A serum free light chain assay measures the levels of circulating kappa and lambda light chains, and an abnormal ratio between the two can point toward overproduction by a rogue cell clone. Additional workup typically includes testing blood and urine for abnormal proteins (serum protein electrophoresis and urine immunofixation) and a bone marrow biopsy to identify the underlying blood cell disorder and determine whether myeloma is present.
Treatment Approaches
There are no established evidence-based guidelines specifically for LCDD, so treatment is adapted from therapies used for related plasma cell disorders. The core goal is the same across all approaches: eliminate or drastically reduce the abnormal cell clone producing the excess light chains. When the source is shut off, deposits can stabilize or slowly clear, and kidney function may improve.
Chemotherapy regimens that target plasma cells are the most common first-line treatment. These typically combine a proteasome inhibitor (which disrupts the internal recycling system of cancer cells, causing them to die) with a steroid and sometimes an additional chemotherapy agent. Some patients are treated with older alkylating-agent-based chemotherapy combined with steroids. The specific regimen depends on the severity of the disease, the patient’s overall health, and whether myeloma is also present.
For eligible patients, high-dose chemotherapy followed by autologous stem cell transplant is a feasible option. In a European registry study, the rate of deep hematologic response (very good partial response or better) improved from 41% before transplant to 66% at 100 days afterward. Six-year overall survival after transplant was 88%, and no patient who was off dialysis at the time of transplant became dialysis-dependent within the first 100 days. Even patients already on dialysis at the time of transplant could safely undergo the procedure.
Kidney Outcomes and Prognosis
How well the kidneys fare depends heavily on two factors: how much kidney function remains at diagnosis and how well the underlying blood disorder responds to treatment. In a long-term study published in Blood, patients diagnosed at an earlier stage of kidney disease (stage 2 or 3) remained free of dialysis for a median of 9 years, compared with only 2.7 years for those diagnosed at stage 4 or 5. About 62% of patients in that cohort eventually required dialysis, with a median survival of 5.2 years after starting it.
The response to chemotherapy is the strongest predictor of kidney trajectory. Patients who achieved a complete or very good partial hematologic response saw their kidney filtration rate improve by an average of about 6 mL/min per year. Those who had only a partial or no response lost kidney function at a similar rate in the opposite direction, roughly 6.5 mL/min per year, and most progressed to end-stage kidney disease. Only 3 of 21 patients who achieved a deep hematologic response in that study ever needed dialysis, compared with 7 of 11 who did not respond well.
Interestingly, the specific pattern of scarring seen on biopsy did not predict kidney outcomes. Neither the presence of nodular glomerulosclerosis nor the degree of tissue fibrosis was significantly associated with how long the kidneys continued to function. What mattered was catching the disease before too much filtration capacity was lost and then achieving a strong treatment response.
Kidney Transplant After LCDD
For patients who do progress to end-stage kidney disease and respond well to treatment of the underlying blood disorder, kidney transplantation is an option. In the European stem cell transplant registry study, the cumulative rate of kidney transplantation at four years after stem cell transplant was 27%, with transplants performed at a median of about two years afterward. Achieving and maintaining a deep hematologic remission before kidney transplant is critical, because persistent light chain production can cause the disease to recur in the new kidney.